

PCT



Attorney Docket: 26797U
 Date: December 14, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
 BRAUNGER, et al.

Art Unit: Unknown
 Examiner: Unknown

Serial No.: 10/542,088

Filed: July 13, 2005

Title: **PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS**

TRANSMITTAL LETTER

Commissioner of Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:


Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- 1) Supplemental Information Disclosure Statement;
- 2) Supplemental PTO Form-1449 with 3 cited References;
- 3) Copies of the 3 cited References.


The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,
NATH & ASSOCIATES PLLC

By:


 Gary M. Nath, Reg. No. 26,965
 Sheldon M. McGee, Reg. No. 50,454
 Customer No. 34375

NATH & ASSOCIATES PLLC
 112 South West Street,
 Alexandria, VA 22314
 GMN/SMM/LE (SIDS)



Attorney Docket: 26797U
Date: December 14, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Art Unit: Unknown
BRAUNGER, et al. Examiner: Unknown
Serial No.: 10/542,088
Filed: July 13, 2005
Title: PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

- [XXX] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- [] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.
The enclosed statement is accompanied by [check one]:
[] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or
[] ii. a check in the amount required by 37 C.F.R. 1.17(p).
- [] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

[] Certification report(e) below; and
[] a check in the amount as required by 1.17(p).

[] d. The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

[] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

[] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[] Appropriate certification is attached.

[XXX] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[XXX] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or

[] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

and/or

[] Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC

By: 

Gary M. Nath, Reg. No. 26,965
Sheldon M. McGee, Reg. No. 50,454
Customer No. 34375

NATH & ASSOCIATES PLLC
112 South West Street,
Alexandria, VA 22314
GMN/SMM/LE (SIDS.STATEMENT)

FORM PTO-1449 <u>INFORMATION DISCLOSURE CITATION</u>		In re Application of: BRAUNGER, et al.		Art Unit: Unknown
		Serial No: 10/542,088	Filed: July 13, 2005	Examiner: Unknown
U.S. PATENT DOCUMENTS				
Examiner Initial	Document Number	Issue / Publication Date	Inventor	Filed
A1				
A2				
A3				
A4				
FOREIGN PATENT DOCUMENTS				
	Document Number	Publication Date	Country	Translation
A5				
A6				
A7				
A8				
A9				
A10				
A11				
A12				
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)				
A13	Lerner, A., et al., "The cAMP Signaling Pathway as a Therapeutic Target in Lymphoid Malignancies", <u>Leukemia and Lymphoma</u> , Vol. 37, Nos. 1-2, Pages 39-51, (2000).			
A14	Dornnife, R.E., et al., "Phosphodiesterase 4 (PDE4) Inhibitors Provide Selective Chemoprotection of Human Neutrophil Progenitors from Phase-Specific Anti-Cancer Agents with No Effect on Anti-Neoplastic Potency", <u>Blood</u> , Vol. 96, No. 11, Page 20A, Abstract #73, (2000).			
A15	Dornnife, R.E., et al., "Selective Chemoprotection of Human Neutrophil Progenitors and Mink Lung Epithelial Cells by Phosphodiesterase 4 (PDE4) Inhibitors In Vitro from the Toxicities of Phase-Specific Anti-Cancer Agents with No Effect of Anti-Neoplastic Potency", <u>Proceedings of the American Association for Cancer Research</u> , Vol. 42, Page 189, #1011, (2001).			
A16				
Examiner		Date Considered		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.				